Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 493 of 6351
-
New hope for transplant patients: shorter drug course may beat stubborn virus
Disease control Recruiting nowTo comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.
Phase 3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Gene-Edited immune cells take on Hard-to-Treat myeloma in early trial
Disease control PausedThis phase Ib trial tests the safety, side effects and best dose of clustered regularly interspaced short palindromic repeats (CRISPR) delivered anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells (1XX BCMA CAR-T cells) in treating patients with multiple…
Phase 1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for advanced cervical cancer: drug combo trial launches
Disease control Not yet recruitingThis is a Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study to evaluate the efficacy of WX390 in combination with toripalimab versus investigator's choice of therapy in patients with recurrent or metastatic cervical cancer who have failed at least one prior…
Phase 3 • Sponsor: Shanghai Jiatan Pharmatech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could stem cell particles restore hearing? new trial begins.
Disease control Not yet recruitingThe goal of this clinical trial is to learn if small extracellular vesicles derived from mesenchymal stem cells work to treat severe and above sudden sensorineural hearing loss. It will also learn about the safety of small extracellular vesicles. The main questions it aims to ans…
Phase 1/2 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for lymphoma patients: experimental drug combo enters human trials
Disease control Not yet recruitingThis is a prospective, multicenter, open-label Phase Ib/II clinical study designed to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics of lisatoclax in combination with R-CHOP or Pola-R-CHP in patients with previously untreated diffuse large B-cell ly…
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New CAR-T therapy SYNCAR-100 enters early human testing for tough leukemia
Disease control Recruiting nowThe purpose of this study is to assess the safety, tolerability, and preliminary efficacy of SYNCAR-100 in patients with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Participants who have signed the informed consent form will undergo scree…
Early phase 1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Aging clock test: tirzepatide trial targets biological age
Disease control Recruiting nowThis pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will be randomized to receive either tirzepatide 2.5 mg s…
Phase 2 • Sponsor: The University of Texas Medical Branch, Galveston • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for stomach cancer: experimental drug combo targets tough tumors
Disease control Recruiting nowThis is A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1/2 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New hope for ovarian cancer: drug combo targets relapsed patients
Disease control Not yet recruitingThis study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients
Phase 2 • Sponsor: Onconic Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden prostate cancer
Diagnosis Not yet recruitinga Phase II, single-arm, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and the effectiveness of near-infrared fluorescence imaging during surgery.
Phase 2 • Sponsor: Haitao Niu, MD • Aim: Diagnosis
Last updated Jun 27, 2026 09:01 UTC
-
Stomach cancer hope: triple therapy may boost tumor clearance before surgery
Disease control Not yet recruitingThis study is a prospective, multicenter, randomized, phase II clinical trial enrolling patients with resectable locally advanced gastric or gastroesophageal junction adenocarcinoma. The study aims to compare the efficacy and safety of perioperative chemotherapy combined with low…
Phase 2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug telitacicept aims to tame Sjögren's in major trial
Disease control Recruiting nowPhase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
Phase 3 • Sponsor: Vor Biopharma • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New hope for hepatitis delta: can switching drugs clear the virus?
Disease control Recruiting nowThis is a Phase 2b/3, randomized, open-label, multicenter trial evaluating the efficacy and safety of switching from bulevirtide to brelovitug for the treatment of chronic hepatitis Delta infection (CHD).
Phase 2/3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Could a Weight-Loss drug curb meth addiction? new trial aims to find out
Disease control Recruiting nowGEM is a two-phase study to evaluate the use of semaglutide (Wegovy) for the treatment of methamphetamine use disorder (MeUD). The first phase is a pilot study, which will be an open-label, single-arm pilot study of 25 participants. Participants will receive Wegovy over a 12-wee…
Phase 2 • Sponsor: San Francisco Department of Public Health • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for ovarian cancer: targeted drug T-DXd tested after standard treatments fail
Disease control Recruiting nowOvarian, fallopian tube, and peritoneal cancers are often diagnosed at an advanced stage, requiring chemotherapy. Recently, the standard treatment, platinum-based chemotherapy plus PARP inhibitors, has extended disease-free survival (PFS). However, most patients eventually develo…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New combo therapy shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis is a single-arm interventional study targeting patients with initially unresectable MSS-type advanced colorectal cancer with liver and/or lung and peritoneal metastasis. Patients will receive lymph node-sparing modified short-course radiotherapy combined with tislelizumab, C…
Phase 2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
AI boosts colonoscopy: finding hidden cancer clues
Diagnosis Not yet recruitingThe investigators conducted a multicenter randomized controlled trial to explore the adjuvant effect of artificial intelligence in the detection of precancerous lesions in the proximal colon.This is a prospective, multicenter, single-blind, parallel randomized controlled trial.Du…
Sponsor: Limian Er • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
New combo therapy aims to outsmart Drug-Resistant breast cancer
Disease control Not yet recruitingThis study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. This study aims to investigate the efficacy and safety of Famitinib combination with SHR-A1811 in CDK4/6 inhibitors-resistent advanced HR+/HER2- breast cancer with SNF4 subtype.
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New blood test could spot hidden breast cancer before scans do
Disease control Recruiting nowThis is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional neoadjuvant chemo-immunotherapy followed by surgery. Te…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Personalized cell therapy takes on advanced melanoma in new trial
Disease control Not yet recruitingThis is a multicenter, randomized controlled, open-label Phase II clinical study designed to evaluate the efficacy and safety of HS-IT101 Injection versus the investigator's choice of chemotherapy in participants with advanced melanoma. A total of 90 participants are planned to b…
Phase 2 • Sponsor: Qingdao Sino-Cell Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC